Combined with prognostic nutritional index and IgM for predicting the clinical outcomes of gastric cancer patients who received surgery

被引:1
作者
Du, Zhongze [1 ]
Sun, Hao [1 ]
Zhao, Ruihu [1 ]
Deng, Guiming [1 ]
Pan, Hongming [1 ]
Zuo, Yanjiao [1 ]
Huang, Rong [1 ]
Xue, Yingwei [1 ]
Song, Hongjiang [1 ]
机构
[1] Harbin Med Univ, Canc Hosp, Dept Gastrointestinal Surg, Harbin, Heilongjiang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
prognostic nutritional index; IgM; gastric cancer; surgery; prognosis; NEOADJUVANT CHEMOTHERAPY; PLUS CISPLATIN; D2; GASTRECTOMY; CAPECITABINE; CACHEXIA; SURVIVAL; THERAPY; TRIAL; SCORE; PNI;
D O I
10.3389/fonc.2023.1113428
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveAlthough the survival rate of patients who undergo surgery for gastric cancer has greatly improved, still many patients have a poor prognosis. This retrospective study aimed to investigate the predictive ability of the PNI-IgM score, a combined prognostic nutritional index (PNI), and immunoglobulin M (IgM), on the prognosis of patients undergoing surgery for gastric cancer. Methods340 patients with gastric cancer who underwent surgery from January 2016 to December 2017 were selected. The PNI-IgM score ranged from 1 to 3: score of 1, low PNI (< 48.45) and low IgM (< 0.87); score of 2, low PNI and high IgM, or high PNI and low IgM; score of 3, high PNI and high IgM. We compared the differences in disease-free survival (DFS) and overall survival (OS) among the three groups, while univariate and multivariate analyses calculated prognostic factors for DFS and OS. In addition, the nomograms were constructed based on the results of multivariate analysis to estimate the 1-, 3- and 5-year survival probability. ResultsThere were 67 cases in the PNI-IgM score 1 group, 160 cases in the PNI-IgM score 2 group, and 113 cases in the PNI-IgM score 3 group. The median survival times of DFS in the PNI-IgM score group 1, the PNI-IgM score group 2, and the PNI-IgM score group 3 were 62.20 months, not reached, and not reached, and 67.57 months vs. not reached vs. not reached in three groups for OS. Patients in the PNI-IgM score group 1 had a lower DFS than the PNI-IgM score group 2 (HR = 0.648, 95% CI: 0.418-1.006, P = 0.053) and the PNI-IgM score group 3 (HR = 0.337, 95% CI: 0.194-0.585, P < 0.001). In stratified analysis, PNI-IgM score 1 had a worse prognosis in the age < 60 years group and CA724 < 2.11 U/m group. ConclusionPNI-IgM score is a novel combination of nutritional and immunological markers that can be used as a sensitive biological marker for patients with gastric cancer who undergo surgery. The lower the PNI-IgM score, the worse the prognosis.
引用
收藏
页数:14
相关论文
共 49 条
  • [1] International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)
    Arnold, Melina
    Morgan, Eileen
    Bardot, Aude
    Rutherford, Mark J.
    Ferlay, Jacques
    Little, Alana
    Moller, Bjorn
    Bucher, Oliver
    De, Prithwish
    Woods, Ryan R.
    Saint-Jacques, Nathalie
    Gavin, Anna T.
    Engholm, Gerda
    Achiam, Michael P.
    Porter, Geoff
    Walsh, Paul M.
    Vernon, Sally
    Kozie, Serena
    Ramanakumar, Agnihotram, V
    Lynch, Charlotte
    Harrison, Samantha
    Merrett, Neil
    O'Connell, Dianne L.
    Mala, Tom
    Elwood, Mark
    Zalcberg, John
    Huws, Dyfed W.
    Ransom, David
    Bray, Freddie
    Soerjomataram, Isabelle
    [J]. GUT, 2022, 71 (08) : 1532 - 1543
  • [2] Immune Surveillance by Natural IgM Is Required for Early Neoantigen Recognition and Initiation of Adaptive Immunity
    Atif, Shaikh M.
    Gibbings, Sophie L.
    Redente, Elizabeth F.
    Camp, Faye A.
    Torres, Raul M.
    Kedl, Ross M.
    Henson, Peter M.
    Jakubzick, Claudia, V
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2018, 59 (05) : 580 - 591
  • [3] Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Bang, Yung-Jue
    Kim, Young-Woo
    Yang, Han-Kwang
    Chung, Hyun Cheol
    Park, Young-Kyu
    Lee, Kyung Hee
    Lee, Keun-Wook
    Kim, Yong Ho
    Noh, Sang-Ik
    Cho, Jae Yong
    Mok, Young Jae
    Kim, Yeul Hong
    Ji, Jiafu
    Yeh, Ta-Sen
    Button, Peter
    Sirzen, Florin
    Noh, Sung Hoon
    [J]. LANCET, 2012, 379 (9813) : 315 - 321
  • [4] Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
    Chen, Li
    Sun, Hao
    Zhao, Ruihu
    Huang, Rong
    Pan, Hongming
    Zuo, Yanjiao
    Zhang, Lele
    Xue, Yingwei
    Li, Xingrui
    Song, Hongjiang
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
    Chen, Li
    Bai, Ping
    Kong, Xiangyi
    Huang, Shaolong
    Wang, Zhongzhao
    Wang, Xiangyu
    Fang, Yi
    Wang, Jing
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [6] Evaluation of IgG, IgM, CD4+ and CD8+ T cells during neoadjuvant chemotherapy with Tezio and Apatinib in gastric cancer patients
    Cui, Zhe
    Zhang, Jianjun
    Zhang, Jing
    Xu, Lan
    [J]. CELLULAR AND MOLECULAR BIOLOGY, 2020, 66 (03) : 113 - 118
  • [7] Cancer-related inflammation and treatment effectiveness
    Diakos, Connie I.
    Charles, Kellie A.
    McMillan, Donald C.
    Clarke, Stephen J.
    [J]. LANCET ONCOLOGY, 2014, 15 (11) : E493 - E503
  • [8] Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer
    Diaz-Zaagoza, Mariana
    Hernandez-Avila, Ricardo
    Viedma-Rodriguez, Rubi
    Arenas-Aranda, Diego
    Ostoa-Saloma, Pedro
    [J]. ONCOLOGY REPORTS, 2015, 34 (03) : 1106 - 1114
  • [9] Absolute monocyte and lymphocyte count prognostic score for patients with gastric cancer
    Eo, Wan Kyu
    Jeong, Da Wun
    Chang, Hye Jung
    Won, Kyu Yeoun
    Choi, Sung Il
    Kim, Se Hyun
    Chun, Sung Wook
    Oh, Young Lim
    Lee, Tae Hwa
    Kim, Young Ok
    Kim, Ki Hyung
    Ji, Yong Il
    Kim, Ari
    Kim, Heung Yeol
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (09) : 2668 - 2676
  • [10] Cancer cachexia: Developing multimodal therapy for a multidimensional problem
    Fearon, K. C. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (08) : 1124 - 1132